^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rituxan (rituximab)

    i
    Other names: R-105, RG-105, RO-45 2294, IDEC 102, RG105, IDEC-C2B8, RO-452294, R 105, RG 105, IDEC-102, R105, IDEC-C2B8 anti-CD20, RO 45-2294, Ro 45-2294, RO452294, RO 452294, IDEC102, IDEC C2BB
    Company:
    Biogen, Roche, Zenyaku Holdings
    Drug class:
    CD20 inhibitor
    Related drugs:
    1d
    Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    1d
    SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1/2, N=48, Recruiting, University of California, San Diego | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Rituxan (rituximab)
    1d
    COMPARE: Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, Charite University, Berlin, Germany | Not yet recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Jun 2027 | Trial primary completion date: Mar 2027 --> Jun 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab)
    1d
    A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Recruiting, Jennifer Crombie, MD | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    2d
    Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma. (PubMed, Cureus)
    We could achieve successful mobilization and stem cell collection with BR120 salvage therapy in two cases.
    P2 data • Journal
    |
    CD34 (CD34 molecule)
    |
    Rituxan (rituximab) • bendamustine • plerixafor
    2d
    What to do when the first TNF inhibitor fails in rheumatoid arthritis: stratified expert recommendations from a scoping review and Delphi consensus. (PubMed, Ther Adv Musculoskelet Dis)
    Agreed positions included caution with JAK inhibitors (JAKi) in older patients and in those with CV/VTE risk; preference for IL-6 receptor inhibitors or JAKi for monotherapy or prominent systemic inflammation; in RA-ILD, use a b/tsDMARD with a non-TNFi mechanism; rituximab as first choice in rheumatoid vasculitis; abatacept in infection-prone patients; discouraging JAKi in prior malignancy; and TNFi as acceptable during pregnancy. Two statements did not reach consensus: preferential use of non-TNFi in obesity and heightened caution with tofacitinib in osteoporosis or fracture risk. This Delphi-validated, profile-based framework provides a practical tool to support evidence-informed clinical decision-making.
    Journal
    |
    IL6 (Interleukin 6)
    |
    Rituxan (rituximab) • tofacitinib • Orencia (abatacept)
    2d
    Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Feb 2026 --> Feb 2027
    Trial initiation date
    |
    ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22)
    |
    ALK negative
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    2d
    Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL (clinicaltrials.gov)
    P2, N=50, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    2d
    BGB-11417-303: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov)
    P3, N=630, Recruiting, BeOne Medicines
    Trial initiation date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    2d
    CAVALRY: CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL (clinicaltrials.gov)
    P1/2, N=104, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Truqap (capivasertib) • nelarabine
    3d
    A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (clinicaltrials.gov)
    P2, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • dexamethasone • fludarabine IV
    3d
    CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: An Unusual Presentation. (PubMed, Am J Dermatopathol)
    Treatment with a rituximab-bevacizumab combination regimen induced a second complete remission, sustained for six months at the time of reporting. Our case highlights the importance of routine CD5 testing in PCDLBCL-LT to identify this distinct subgroup and to guide appropriate differential diagnosis and patient monitoring.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    Avastin (bevacizumab) • Rituxan (rituximab)